Dr Pawan G Nayak

Assistant Professor

Date of Joining: 04.11.2020

Department of Pharmacology

CURRENT ACADEMIC ROLE & RESPONSIBILITIES

    Pawan G Nayak is an Assistant Professor?in the Department of Pharmacology at MCOPS

    • Handles Pharmacology for DPharm and MPharm students
    • Provides training regarding standard procedures to be adopted in the laboratory

SUBJECTS CURRENTLY TEACHING

Subject Semester / Year
Pharmacology and Toxicology (Theory and Lab) DPharm Part-II
Pharmacology Practicals II 2nd semester MPharm
必威体育betway888 work III and IV semester MPharm

ACADEMIC QUALIFICATIONS

Degree Specialisation Institute Year of passing
PhD Pharmaceutical Sciences 必威体育betway888 Academy of Higher Education 2018
MPharm Pharmacology 必威体育betway888 University 2008
BPharm --- 必威体育betway888 Academy of Higher Education 2006

Experience

Institution / Organisation Designation Role Tenure
Department of Pharmacology, MCOPS Assistant Professor Teaching and 必威体育betway888 November 2020
Department of Pharmacology, MCOPS Senior 必威体育betway888 Fellow in DST-SERB funded project 必威体育betway888 July 2019 – October 2020
Department of Pharmacology, MCOPS 必威体育betway888 Coordinator in industry funded projects 必威体育betway888 May 2018 – June 2019
Department of Pharmacology, MCOPS Senior 必威体育betway888 Fellow in DST-SERB funded project 必威体育betway888 April 2016 – March 2018
Department of Pharmacology, MCOPS 必威体育betway888 Scholar in industry funded project 必威体育betway888 February 2009 – April 2016

Strategy to combat statin-induced diabetes and its complications.

July 2019 – October 2020

SERB under DST, GoI (Senior 必威体育betway888 Fellow in DST-SERB funded project)

May 2018 – June 2019

必威体育betway888 Coordinator in industry funded projects (Under Dr. K. Nandakumar (PI), Professor, MCOPS for Jagadale Industries, Pvt. Ltd., Bengaluru)

Development of novel quercetin analogues intended for selective HDAC-8 inhibition as beneficial anti-cancer agents.

April 2016 – March 2018

Senior 必威体育betway888 Fellow in DST-SERB funded project (SERB under DST, GoI)

Preclinical evaluation of new chemical entities for anticlastogenic activity

February 2009 – April 2016

必威体育betway888 Scholar in industry funded project (Bristol Laboratories Ltd., Bristol, UK)

AREAS OF INTEREST, EXPERTISE AND RESEARCH

Area of Interest

Pharmacology, Toxicology, Cellular and Molecular biology

Area of Expertise

Preclinical testing and cell-based assays for the evaluation of new chemical entities, formulations and ayurvedic preparations

Area of 必威体育betway888

Preclinical drug discovery in the following therapeutic areas – inflammation, wound healing, cardiometabolic, neurological and oncological disorders

Professional Affiliations & Contributions

  • Life Member of Indian Pharmacological Society (IPS)

Total number of publications: 51

Please browse the following link- https://manipal.pure.elsevier.com/en/persons/pawan-g-nayak

Botrops derived hemocoagulase formulation a probable agent for diabetic wound healing

2020 Keni, R Gourishetti, K Kinra, M Nayak, P.G Shenoy, R Nandakumar, K Jagdale, R.N Raghavendra, K.V Ahmed, S.M.

3 Biotech, 10 (10), art. no. 443. DOI: 10.1007/s13205-020-02429-5

COVID-19: Emergence, Spread, Possible Treatments, and Global Burden

2020 Keni, R Alexander, A Nayak, P.G Mudgal, J Nandakumar, K

Frontiers in Public Health, 8, art. no. 216. DOI: 10.3389/fpubh.2020.00216

Medhya rasayana restores memory function against doxorubicin-induced cognitive decline: Possibly by its neuroprotective effect

2019 Gourishetti, K Ghetia, S Jacob, L., Mallik, S.B Nayak, P.G Kishore, A Nandakumar, K Alnaseer, S.M Hussain, S.M

Indian Journal of Pharmaceutical Education and 必威体育betway888, 53 (2), pp. S104-S111. DOI: 10.5530/ijper.53.2s.54

In vivo Evaluation of Two Thiazolidin-4-one Derivatives in High Sucrose Diet Fed Pre-diabetic Mice and Their Modulatory Effect on AMPK, Akt and p38 MAP Kinase in L6 Cells

Mudgal J Shetty P Nayak PG Kumar N Kishore A Kutty NG Nandakumar K Shenoy RR Rao CM Joseph A et al

Front Pharmacol. 2016 Oct 14;7:381

Female rats induced with mammary cancer as a relevant animal model for doxorubicin-induced chemobrain in vivo

Ramalingayya GV Nayak PG Shenoy RR Rao CM Nandakumar K

Clin Exp Pharmacol Physiol. 2016 Sep;43(9):862-3. doi: 10.1111/1440-1681.12596. No abstract available. Erratum in: Clin Exp Pharmacol Physiol. 2016 Oct;43(10):1017

Naringin and Rutin Alleviates Episodic Memory Deficits in Two Differentially Challenged Object Recognition Tasks

Ramalingayya GV Nampoothiri M Nayak PG Kishore A Shenoy RR Mallikarjuna Rao C Nandakumar K

Pharmacogn Mag. 2016 Jan;12(Suppl 1):S63-70. doi: 10.4103/0973-1296.176104.